ClinicalTrials.gg
CompletedNCT02586025PEONYUpdated May 22, 2023Results posted

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

A Phase 3 interventional study of FEC Chemotherapy and Surgery in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-22.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
329
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
25th of 104
329 · median 100
Started
2016
with 5 others
Phase 3
23 of 104
2 open now
Registered
39th of 104
by date
Lead sponsor
20 of 104
Hoffmann-La Roche

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 25th largest by enrollment, is one of 6 that started in 2016, is one of 23 in phase 3, and was the 39th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This is an Asia-Pacific regional, randomized, double-blind, multicenter trial designed to evaluate treatment with trastuzumab + pertuzumab + docetaxel compared with trastuzumab + placebo + docetaxel in chemotherapy-naïve participants with early-stage or locally advanced HER2-positive breast cancer. The anticipated treatment duration is approximately 17 months.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed invasive breast carcinoma with a primary tumor size of more than (>) 2 centimeters (cm) by standard local assessment technique
  • Breast cancer stage at presentation: early-stage (T2-3, N0-1, M0) or locally advanced (T2-3, N2 or N3, M0; T4, any N, M0)
  • -positive breast cancer confirmed by a Sponsor-designated central laboratory and defined as 3+ score by immunohistochemistry in > 10 percent (%) of immunoreactive cells or HER2 gene amplification (ratio of HER2 gene signals to centromere 17 signals equal to or more than [>=] 2.0) by in situ hybridization
  • Known hormone receptor status (estrogen receptor and/or progesterone receptor)
  • Performance Status equal to or less than (\<=) 1
  • Baseline left ventricular ejection fracture >= 55% measured by echocardiography (preferred) or multiple gated acquisition scan
  • Negative serum pregnancy test

Exclusion criteria

Exclusion Criteria:

  • Stage IV breast cancer
  • Inflammatory breast cancer
  • Previous anti-cancer therapy or radiotherapy for any
  • History of other malignancy within 5 years prior to screening, except for appropriately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
  • Concurrent anti-cancer treatment in another trial, including hormone therapy, bisphosphonate therapy, or immunotherapy
  • Major surgical procedure unrelated to breast cancer within 4 weeks prior to randomization or from which the participant has not fully recovered
  • Serious cardiac illness or medical condition
  • Other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness
  • Any abnormalities in liver, kidney or hematologic function laboratory tests immediately prior to randomization
  • Sensitivity to any of the study medications, any of the ingredients or of these medications, or benzyl alcohol
  • Pregnant or lactating
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
329 participants (actual)

Study arms

  • Experimental
    Trastuzumab, Pertuzumab, and Chemotherapy

    Prior to surgery: trastuzumab, pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with 5-fluorouracil, epirubicin, and cyclophosphamide (FEC): trastuzumab and pertuzumab up to 1 year total.

    Drug: FEC Chemotherapy · Procedure: Surgery · Drug: Docetaxel · Drug: Pertuzumab · Drug: Trastuzumab

  • Experimental
    Trastuzumab, Placebo, and Chemotherapy

    Prior to surgery: trastuzumab, placebo, and docetaxel for 4 cycles (1 cycle = 21 days). After surgery/FEC chemotherapy: trastuzumab and placebo up to 1 year total.

    Drug: FEC Chemotherapy · Procedure: Surgery · Drug: Docetaxel · Drug: Placebo · Drug: Trastuzumab

Interventions

  • DrugFEC Chemotherapy

    Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.

  • ProcedureSurgery

    All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.

  • Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.

  • Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4. After surgery and 3 cycles of FEC chemotherapy (adjuvant treatment): 840 mg loading dose for Cycle 8, followed by 420 mg for Cycles 9-20)

    Also known as: RO4368451

  • DrugPlacebo

    Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)

  • Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.

    Also known as: RO0452317

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC)

    This tpCR was assessed by the IRC. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current American Joint Committee on Cancer \[AJCC\] staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.

    Time frame: At surgery (Cycle 4 Days 22-35)

Secondary outcomes

  1. Percentage of Participants With tpCR as Assessed by the Local Pathologist

    This tpCR was assessed by the local pathologist. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.

    Time frame: At surgery (Cycle 4 Days 22-35)

  2. Percentage of Participants With Breast Pathologic Complete Response (bpCR), Defined as ypT0/is According to the AJCC Staging System as Assessed by the IRC

    This bpCR was assessed by the IRC. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is, in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.

    Time frame: At surgery (Cycle 4 Days 22-35)

  3. Percentage of Participants With bpCR as Assessed by the Local Pathologist

    This bpCR was assessed by the local pathologist. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.

    Time frame: At surgery (Cycle 4 Days 22-35)

  4. Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

    Clinical responses that include percentage of participants with a CR, PR, SD, or PD were determined by investigator during Cycles 1-4 (prior to surgery) on basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum during the study. PD=at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (nadir) with inclusion of baseline. Only participants with measurable disease at baseline were included in the analysis. 1 Cycle=21 days. The percentages have been rounded off to first decimal point.

    Time frame: At surgery (Cycle 4 Days 22-35)

  5. Percentage of Participants With an Objective Response (CR or PR) During Cycles 1-4, According to RECIST Version 1.1

    An objective response was defined as the percentage of participants who achieved a CR or PR as the best tumor response during the neoadjuvant period (that is, during Cycles 1-4 prior to surgery), as determined by the investigator on the basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. No confirmation was required for objective response. Only participants with measurable disease at baseline were included in the analysis. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.

    Time frame: At surgery (Cycle 4 Days 22-35)

  6. Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years

    Kaplan-Meier approach was used to estimate percentage of participants who were event-free for EFS at 1, 3 \& 5 years. EFS=time from randomization to first documentation of one of the following events: PD (before surgery) as determined by investigator with RECIST v1.1. PD=at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum during the study (nadir) with inclusion of baseline. Any evidence of contralateral disease in situ was not identified as PD; Disease recurrence (local, regional, distant, or contralateral) after surgery; Death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year \& then every 6 months thereafter, until disease progression/recurrence or until 5 years after randomization of last participant, whichever occurred first. Participants without an EFS event at time of analysis were censored as of the date they were last known to be alive \& event-free.

    Time frame: From Baseline to EFS event or date last known to be alive and event-free at 1, 3, and 5 years

  7. Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years

    Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for DFS at 1, 3 and 5 years. DFS = time from first date of no disease (i.e., date of surgery) to first documentation of one of the following events: Disease recurrence (local, regional, distant, or contralateral) after surgery or death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Participants were considered to be disease-free if they underwent surgery and no recurrence of disease was reported thereafter. Data from participants who did not have an event at analysis were censored as of the date they were last known to be alive and event-free.

    Time frame: From surgery (Cycle 4: Days 22-35) to DFS event or date last known to be alive and event-free at 1, 3, and 5 years

  8. Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years

    Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS at 1, 3 and 5 years. OS was defined as the time from randomization to death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Data from participants who were alive at the time of the analysis was censored as of the last date they were known to be alive.

    Time frame: From Baseline to OS event or date last known to be alive at 1, 3, and 5 years

  9. Percentage of Participants With at Least One Adverse Event (AE) During the Neoadjuvant Treatment Period

    The percentage of participants who experienced at least one AE during the neoadjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. The neoadjuvant treatment period began after randomization upon receiving the first dose of any of the neoadjuvant study medications and ended before receiving the first dose of adjuvant study treatment. The duration of one treatment cycle is 21 days. The percentages have been rounded off to first decimal point.

    Time frame: Baseline up to end of Cycle 4 (1 cycle = 21 days)

  10. Percentage of Participants With at Least One AE During the Adjuvant Treatment Period

    Percentage of participants who experienced at least one adverse event during the adjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. Adjuvant treatment period began after primary surgery, upon receiving the first dose of any of the adjuvant study medications. It ended 42 days after last dose of adjuvant study treatment upon treatment completion or discontinuation. 1 Cycle=21 days. The percentages have been rounded off to first decimal point.

    Time frame: From Cycle 5 (1 cycle = 21 days) up to 42 days after the last dose in Cycle 20 Day 1 (approximately 1 year)

  11. Percentage of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period

    The percentage of participants who experienced at least one adverse event during the treatment-free follow-up period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. The percentages have been rounded off to first decimal point.

    Time frame: From end of overall study treatment until disease progression or until 5 years after randomization of the last patient, whichever occurred first (up to 6 years)

  12. Percentage of Participants Who Experienced a Primary Cardiac Event

    A primary cardiac event is defined as heart failure (New York Heart Association \[NYHA\] Class III or NYHA Class IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction points from baseline and to below 50%.

    Time frame: From Baseline until end of study (up to 6 years)

  13. Percentage of Participants Who Experienced a Secondary Cardiac Event

    A secondary cardiac event is defined as an asymptomatic or mildly symptomatic (NYHA Class II) drop in LVEF by multiple-gated acquisition (MUGA) scan or echocardiogram confirmed by a second LVEF assessment within approximately 3 weeks showing also a documented drop. A significant LVEF drop is defined as an absolute decrease of at least 10 points below the baseline measurement and to below 50%.

    Time frame: From Baseline until end of study (up to 6 years)

  14. Maximum Change From Baseline in LVEF

    LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the maximum change from baseline in LVEF at any point during the study.

    Time frame: Baseline; Day 1 of Cycles 2, 4, 5, 8, 11, and 20 (1 cycle = 21 days)

  15. Change From Baseline in LVEF Over Time

    LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the change from baseline in LVEF over time.

    Time frame: Baseline; Day 1 of Cycles 2, 4, 5, 8, 11, and 20 (1 cycle = 21 days)

07

Results

Posted Jan 3, 2019

Participant flow

A total of 329 participants with early-stage or locally advanced human epidermal growth factor receptor (HER) 2-positive breast cancer were enrolled in this study at 23 investigative sites in China, Republic of Korea, Taiwan, and Thailand from 14 March 2016 to 14 March 2022.

Neoadjuvant Treatment
Participant flow — Neoadjuvant Treatment
MilestonePertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Started219110
Received at least one dose of study treatment218110
Completed neoadjuvant treatment214108
Underwent surgery210105
Completed208103
Not completed117
Withdrew: Withdrawal by subject43
Withdrew: Progression of disease23
Withdrew: Did not receive study drug10
Withdrew: Death10
Withdrew: Adverse event10
Withdrew: Physician decision21
Adjuvant Treatment
Participant flow — Adjuvant Treatment
MilestonePertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Started208103
Started adjuvant fec treatment208103
Started adjuvant anti-her2 treatment20499
Completed19894
Not completed109
Withdrew: Withdrawal by subject53
Withdrew: Recurrent disease45
Withdrew: Physician decision01
Withdrew: Pregnancy10
Treatment-Free Follow-Up
Participant flow — Treatment-Free Follow-Up
MilestonePertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Started208104
Completed17582
Not completed3322
Withdrew: Death1111
Withdrew: Lost to follow-up94
Withdrew: Withdrawal by subject133
Withdrew: Non-compliance01
Withdrew: Reason not specified03

Outcome measures

PrimaryPercentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC)

This tpCR was assessed by the IRC. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current American Joint Committee on Cancer \[AJCC\] staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.

Time frame:
At surgery (Cycle 4 Days 22-35)
Reported as:
Number · percentage of participants
Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC)
percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Percentage of Participants With Total Pathologic Complete Response (tpCR) as Assessed by the Independent Review Committee (IRC)39.3 (32.76 to 46.08)21.8 (14.51 to 30.70)
Statistical analysis
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Cochran-Mantel-Haenszel · p = 0.0014 (Two-sided significance level of 5%) · Difference in response rates: 17.45 · 95% CI 6.89 to 28.01Pertuzumab, Trastuzumab, Docetaxel arm minus Placebo, Trastuzumab, Docetaxel arm. Approximate 95% CI for difference of two rates using Hauck-Anderson method.
SecondaryPercentage of Participants With tpCR as Assessed by the Local Pathologist

This tpCR was assessed by the local pathologist. tpCR was defined as the absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes after completion of neoadjuvant therapy and surgery (that is, ypT0/is, ypN0, in accordance with the current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose tpCR assessment was missing or invalid were counted as not achieving tpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.

Time frame:
At surgery (Cycle 4 Days 22-35)
Reported as:
Number · percentage of participants
Percentage of Participants With tpCR as Assessed by the Local Pathologist
percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Percentage of Participants With tpCR as Assessed by the Local Pathologist39.3 (32.76 to 46.08)20.9 (13.74 to 29.70)
Statistical analysis
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Cochran-Mantel-Haenszel · p = 0.0008 (Two-sided significance level of 5%) · Difference in response rates: 18.36 · 95% CI 7.89 to 28.83Pertuzumab, Trastuzumab, Docetaxel arm minus Placebo, Trastuzumab, Docetaxel arm. Approximate 95% CI for difference of two rates using Hauck-Anderson method.
SecondaryPercentage of Participants With Breast Pathologic Complete Response (bpCR), Defined as ypT0/is According to the AJCC Staging System as Assessed by the IRC

This bpCR was assessed by the IRC. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is, in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.

Time frame:
At surgery (Cycle 4 Days 22-35)
Reported as:
Number · percentage of participants
Percentage of Participants With Breast Pathologic Complete Response (bpCR), Defined as ypT0/is According to the AJCC Staging System as Assessed by the IRC
percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Percentage of Participants With Breast Pathologic Complete Response (bpCR), Defined as ypT0/is According to the AJCC Staging System as Assessed by the IRC42.0 (35.39 to 48.85)23.6 (16.06 to 32.68)
Statistical analysis
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Cochran-Mantel-Haenszel · p = 0.0010 (Two-sided significance level of 5%) · Difference in response rates: 18.37 · 95% CI 7.60 to 29.15Pertuzumab, Trastuzumab, Docetaxel arm minus Placebo, Trastuzumab, Docetaxel arm. Approximate 95% CI for difference of two rates using Hauck-Anderson method.
SecondaryPercentage of Participants With bpCR as Assessed by the Local Pathologist

This bpCR was assessed by the local pathologist. bpCR was defined as the absence of any residual invasive cancer on the hematoxylin and eosin evaluation of the resected breast specimen after completion of neoadjuvant therapy and surgery (that is, ypT0/is in accordance with current AJCC staging system). The analysis was based on the ITT population with participants grouped by the treatment assigned at the time of randomization. Participants whose bpCR assessment was missing or invalid were counted as not achieving bpCR. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.

Time frame:
At surgery (Cycle 4 Days 22-35)
Reported as:
Number · percentage of participants
Percentage of Participants With bpCR as Assessed by the Local Pathologist
percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Percentage of Participants With bpCR as Assessed by the Local Pathologist41.6 (34.95 to 48.39)22.7 (15.28 to 31.70)
Statistical analysis
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Cochran-Mantel-Haenszel · p = 0.0006 (Two-sided significance level of 5%) · Difference in response rates: 18.83 · 95% CI 8.14 to 29.51Pertuzumab, Trastuzumab, Docetaxel arm minus Placebo, Trastuzumab, Docetaxel arm. Approximate 95% CI for difference of two rates using Hauck-Anderson method.
SecondaryPercentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1

Clinical responses that include percentage of participants with a CR, PR, SD, or PD were determined by investigator during Cycles 1-4 (prior to surgery) on basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeters (mm). PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD=neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum during the study. PD=at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum during the study (nadir) with inclusion of baseline. Only participants with measurable disease at baseline were included in the analysis. 1 Cycle=21 days. The percentages have been rounded off to first decimal point.

Time frame:
At surgery (Cycle 4 Days 22-35)
Reported as:
Number · percentage of participants
Percentage of Participants With Complete Response (CR), Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD) During Cycles 1-4, According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Complete Response11.0 (7.15 to 15.87)10.0 (5.10 to 17.19)
Partial Response77.6 (71.52 to 82.97)68.2 (58.62 to 76.74)
Stable Disease8.2 (4.94 to 12.68)19.1 (12.22 to 27.69)
Progressive Disease0.5 (0.01 to 2.52)1.8 (0.22 to 6.41)
Missing or Unevaluable2.7 (NA to NA)0.9 (NA to NA)
SecondaryPercentage of Participants With an Objective Response (CR or PR) During Cycles 1-4, According to RECIST Version 1.1

An objective response was defined as the percentage of participants who achieved a CR or PR as the best tumor response during the neoadjuvant period (that is, during Cycles 1-4 prior to surgery), as determined by the investigator on the basis of RECIST version 1.1. CR=disappearance of all target lesions i.e., any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR=at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. No confirmation was required for objective response. Only participants with measurable disease at baseline were included in the analysis. The duration of one treatment cycle was 21 days; the administration of therapy in Cycle 5 did not occur until 2 weeks after surgery. The percentages have been rounded off to first decimal point.

Time frame:
At surgery (Cycle 4 Days 22-35)
Reported as:
Number · percentage of participants
Percentage of Participants With an Objective Response (CR or PR) During Cycles 1-4, According to RECIST Version 1.1
percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Percentage of Participants With an Objective Response (CR or PR) During Cycles 1-4, According to RECIST Version 1.188.6 (83.61 to 92.47)78.2 (69.30 to 85.49)
Statistical analysis
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Cochran-Mantel-Haenszel · p = 0.0125 (Two-sided significance level of 5%) · Difference in response rates: 10.40 · 95% CI 1.12 to 19.69Pertuzumab, Trastuzumab, Docetaxel arm minus Placebo, Trastuzumab, Docetaxel arm
SecondaryKaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years

Kaplan-Meier approach was used to estimate percentage of participants who were event-free for EFS at 1, 3 \& 5 years. EFS=time from randomization to first documentation of one of the following events: PD (before surgery) as determined by investigator with RECIST v1.1. PD=at least a 20% increase in sum of diameters of target lesions, taking as reference smallest sum during the study (nadir) with inclusion of baseline. Any evidence of contralateral disease in situ was not identified as PD; Disease recurrence (local, regional, distant, or contralateral) after surgery; Death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year \& then every 6 months thereafter, until disease progression/recurrence or until 5 years after randomization of last participant, whichever occurred first. Participants without an EFS event at time of analysis were censored as of the date they were last known to be alive \& event-free.

Time frame:
From Baseline to EFS event or date last known to be alive and event-free at 1, 3, and 5 years
Reported as:
Number · estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Event-Free Survival (EFS) at 1, 3, and 5 Years
estimate of percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
1 Year98.62 (97.06 to 100.00)90.46 (84.82 to 96.09)
3 Years88.85 (84.55 to 93.15)79.68 (71.91 to 87.45)
5 Years84.80 (79.86 to 89.73)73.70 (65.17 to 82.23)
Statistical analysis
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Stratified log-rank · p = 0.0140 · Hazard ratio (hr): 0.53 · 95% CI 0.32 to 0.89The hazard ratio was calculated by stratified Cox proportional hazards model.
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Z-test · p = 0.0062 · Difference in efs event-free rates: -8.16 · 95% CI -14.00 to -2.32The difference in EFS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm.
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Z-test · p = 0.0429 · Difference in efs event-free rates: -9.17 · 95% CI -18.05 to -0.29The difference in EFS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm.
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Z-test · p = 0.0274 · Difference in efs event-free rates: -11.10 · 95% CI -20.95 to -1.24The difference in EFS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm.
SecondaryKaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years

Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for DFS at 1, 3 and 5 years. DFS = time from first date of no disease (i.e., date of surgery) to first documentation of one of the following events: Disease recurrence (local, regional, distant, or contralateral) after surgery or death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Participants were considered to be disease-free if they underwent surgery and no recurrence of disease was reported thereafter. Data from participants who did not have an event at analysis were censored as of the date they were last known to be alive and event-free.

Time frame:
From surgery (Cycle 4: Days 22-35) to DFS event or date last known to be alive and event-free at 1, 3, and 5 years
Reported as:
Number · estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Disease-Free Survival (DFS) at 1, 3, and 5 Years
estimate of percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
1 Year97.55 (95.42 to 99.67)92.08 (86.81 to 97.35)
3 Years90.09 (85.97 to 94.22)81.10 (73.44 to 88.75)
5 Years85.99 (81.17 to 90.80)75.02 (66.53 to 83.51)
Statistical analysis
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Stratified log-rank · p = 0.0140 · Hazard ratio (hr): 0.52 · 95% CI 0.30 to 0.88The hazard ratio was calculated by stratified Cox proportional hazards model.
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Z-test · p = 0.0592 · Difference in dfs event-free rates: -5.47 · 95% CI -11.15 to 0.21The difference in DFS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm.
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Z-test · p = 0.0426 · Difference in dfs event-free rates: -9.00 · 95% CI -17.69 to -0.30The difference in DFS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm.
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Z-test · p = 0.0276 · Difference in dfs event-free rates: -10.97 · 95% CI -20.73 to -1.21The difference in DFS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm.
SecondaryKaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years

Kaplan-Meier approach was used to estimate the percentage of participants who were event-free for OS at 1, 3 and 5 years. OS was defined as the time from randomization to death from any cause. After treatment completion/discontinuation, follow-up data was collected every 3 months for 1 year and then every 6 months thereafter, until disease progression or recurrence or until 5 years after randomization of the last participant, whichever occurred first. Data from participants who were alive at the time of the analysis was censored as of the last date they were known to be alive.

Time frame:
From Baseline to OS event or date last known to be alive at 1, 3, and 5 years
Reported as:
Number · estimate of percentage of participants
Kaplan-Meier Estimate of the Percentage of Participants Event-Free for Overall Survival (OS) at 1, 3, and 5 Years
estimate of percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
1 Year99.54 (98.64 to 100.00)100.00 (100.00 to 100.00)
3 Years97.01 (94.64 to 99.37)90.99 (85.37 to 96.60)
5 Years93.86 (90.49 to 97.23)89.97 (84.06 to 95.87)
Statistical analysis
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Stratified log-rank · p = 0.1181 · Hazard ratio (hr): 0.53 · 95% CI 0.23 to 1.19The hazard ratio was calculated by stratified Cox proportional hazards model.
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Z-test · p = 0.3162 · Difference in os event-free rates: 0.46 · 95% CI -0.44 to 1.36The difference in OS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm.
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Z-test · p = 0.0529 · Difference in os event-free rates: -6.02 · 95% CI -12.11 to 0.08The difference in OS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm.
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Z-test · p = 0.2616 · Difference in os event-free rates: -3.89 · 95% CI -10.69 to 2.90The difference in OS event-free rates was calculated as the Placebo arm minus the Pertuzumab arm.
SecondaryPercentage of Participants With at Least One Adverse Event (AE) During the Neoadjuvant Treatment Period

The percentage of participants who experienced at least one AE during the neoadjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. The neoadjuvant treatment period began after randomization upon receiving the first dose of any of the neoadjuvant study medications and ended before receiving the first dose of adjuvant study treatment. The duration of one treatment cycle is 21 days. The percentages have been rounded off to first decimal point.

Time frame:
Baseline up to end of Cycle 4 (1 cycle = 21 days)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event (AE) During the Neoadjuvant Treatment Period
percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Percentage of Participants With at Least One Adverse Event (AE) During the Neoadjuvant Treatment Period97.796.4
SecondaryPercentage of Participants With at Least One AE During the Adjuvant Treatment Period

Percentage of participants who experienced at least one adverse event during the adjuvant period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Pre-existing conditions which worsened during the study were also considered as adverse events. Adjuvant treatment period began after primary surgery, upon receiving the first dose of any of the adjuvant study medications. It ended 42 days after last dose of adjuvant study treatment upon treatment completion or discontinuation. 1 Cycle=21 days. The percentages have been rounded off to first decimal point.

Time frame:
From Cycle 5 (1 cycle = 21 days) up to 42 days after the last dose in Cycle 20 Day 1 (approximately 1 year)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One AE During the Adjuvant Treatment Period
percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Percentage of Participants With at Least One AE During the Adjuvant Treatment Period98.198.1
SecondaryPercentage of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period

The percentage of participants who experienced at least one adverse event during the treatment-free follow-up period is reported here. An AE is any untoward medical occurrence in a clinical investigation participant who is administered a pharmaceutical product regardless of the causal attribution. An adverse event was therefore any unfavourable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. The percentages have been rounded off to first decimal point.

Time frame:
From end of overall study treatment until disease progression or until 5 years after randomization of the last patient, whichever occurred first (up to 6 years)
Reported as:
Number · percentage of participants
Percentage of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period
percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Percentage of Participants With at Least One Adverse Event During the Treatment-Free Follow-Up Period6.07.3
SecondaryPercentage of Participants Who Experienced a Primary Cardiac Event

A primary cardiac event is defined as heart failure (New York Heart Association \[NYHA\] Class III or NYHA Class IV) and a drop in left ventricular ejection fraction (LVEF) of at least 10 ejection fraction points from baseline and to below 50%.

Time frame:
From Baseline until end of study (up to 6 years)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced a Primary Cardiac Event
percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Percentage of Participants Who Experienced a Primary Cardiac Event00
SecondaryPercentage of Participants Who Experienced a Secondary Cardiac Event

A secondary cardiac event is defined as an asymptomatic or mildly symptomatic (NYHA Class II) drop in LVEF by multiple-gated acquisition (MUGA) scan or echocardiogram confirmed by a second LVEF assessment within approximately 3 weeks showing also a documented drop. A significant LVEF drop is defined as an absolute decrease of at least 10 points below the baseline measurement and to below 50%.

Time frame:
From Baseline until end of study (up to 6 years)
Reported as:
Number · percentage of participants
Percentage of Participants Who Experienced a Secondary Cardiac Event
percentage of participantsPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Percentage of Participants Who Experienced a Secondary Cardiac Event00
SecondaryMaximum Change From Baseline in LVEF

LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the maximum change from baseline in LVEF at any point during the study.

Time frame:
Baseline; Day 1 of Cycles 2, 4, 5, 8, 11, and 20 (1 cycle = 21 days)
Reported as:
Mean · percentage points of LVEF
Maximum Change From Baseline in LVEF
percentage points of LVEFPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Maximum Change From Baseline in LVEF-6.55 ± 5.22-6.20 ± 6.08
Statistical analysis
  • Pertuzumab, Trastuzumab, and Chemotherapy vs Placebo, Trastuzumab, and Chemotherapy · Mean difference (final values): -0.35 · 95% CI -1.62 to 0.93Pertuzumab, Trastuzumab, Docetaxel arm minus Placebo, Trastuzumab, Docetaxel arm
SecondaryChange From Baseline in LVEF Over Time

LVEF is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram (preferred) or MUGA scan. The same method was used throughout the study for each participant and preferably performed and evaluated by the same assessor. Here, we report the change from baseline in LVEF over time.

Time frame:
Baseline; Day 1 of Cycles 2, 4, 5, 8, 11, and 20 (1 cycle = 21 days)
Reported as:
Mean · percentage points of LVEF
Change From Baseline in LVEF Over Time
percentage points of LVEFPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Cycle 2 Day 1-0.62 (-1.35 to 0.11)0.29 (-0.89 to 1.46)
Cycle 4 Day 1-1.02 (-1.72 to -0.32)0.09 (-1.03 to 1.22)
Cycle 5 Day 1-0.96 (-1.70 to -0.22)0.07 (-1.12 to 1.26)
Cycle 8 Day 1-1.63 (-2.44 to -0.81)-1.18 (-2.30 to -0.05)
Cycle 11 Day 1-1.38 (-2.16 to -0.61)-0.65 (-1.91 to 0.62)
Cycle 20 Day 1-1.22 (-2.05 to -0.38)-1.18 (-2.56 to 0.20)

Adverse events

Collected over From first dose of any study drug through end of study (up to 6 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pertuzumab, Trastuzumab, and Chemotherapy12/218 (5.5%)37/218 (17%)218/218 (100%)
Placebo, Trastuzumab, and Chemotherapy11/110 (10%)15/110 (13.6%)108/110 (98.2%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
Febrile NeutropeniaBlood and lymphatic system disorders9/2183/110
PneumoniaInfections and infestations4/2181/110
MyelosuppressionBlood and lymphatic system disorders3/2180/110
DiarrhoeaGastrointestinal disorders2/2180/110
VomitingGastrointestinal disorders2/2180/110
Liver DisorderHepatobiliary disorders2/2180/110
BacteraemiaInfections and infestations2/2180/110
Urinary Tract InfectionInfections and infestations2/2181/110
AnaemiaBlood and lymphatic system disorders1/2181/110
Blood Loss AnaemiaBlood and lymphatic system disorders0/2181/110
Most frequent other events
Showing 10 of 50
Most frequent other events
EventPertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and Chemotherapy
NeutropeniaBlood and lymphatic system disorders153/21873/110
LeukopeniaBlood and lymphatic system disorders135/21867/110
AlopeciaSkin and subcutaneous tissue disorders115/21856/110
DiarrhoeaGastrointestinal disorders87/21819/110
NauseaGastrointestinal disorders84/21840/110
Alanine Aminotransferase IncreasedInvestigations64/21841/110
AnaemiaBlood and lymphatic system disorders75/21836/110
Aspartate Aminotransferase IncreasedInvestigations54/21834/110
Upper Respiratory Tract InfectionInfections and infestations58/21814/110
RashSkin and subcutaneous tissue disorders28/21822/110

Baseline characteristics

Intent-to-Treat (ITT) population included all participants who were enrolled regardless of whether they received any study treatment.

Age, Continuous
Age, Continuous(years)Pertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and ChemotherapyTotal
Mean48.4 ± 9.749.5 ± 9.148.8 ± 9.5
Age, Customized
Age, Customized(Participants)Pertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and ChemotherapyTotal
<40 years old401858
40-49 years old7540115
50-64 years old9644140
≥65 years old8816
Sex: Female, Male
Sex: Female, Male(Participants)Pertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and ChemotherapyTotal
Female219110329
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Pertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and ChemotherapyTotal
Hispanic or Latino000
Not Hispanic or Latino219110329
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and ChemotherapyTotal
American Indian or Alaska Native000
Asian219110329
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
Disease Category
Disease Category(Participants)Pertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and ChemotherapyTotal
Early Stage15277229
Locally Advanced6733100
Hormone Receptor Status
Hormone Receptor Status(Participants)Pertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and ChemotherapyTotal
Estrogen Receptor (ER) and Progesterone Receptor (PgR) Negative10554159
Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Positive11456170
Baseline LVEF value
Baseline LVEF value(percentage points of LVEF)Pertuzumab, Trastuzumab, and ChemotherapyPlacebo, Trastuzumab, and ChemotherapyTotal
Mean66.41 ± 4.9366.03 ± 5.1966.28 ± 5.01
08

Study locations

23 sites
  • The Affiliated Hospital of Military Medical Sciences(The 307th Hospital of Chinese PLA)
    Beijing, 100071, China
  • the First Hospital of Jilin University
    Changchun, 130021, China
  • Jilin Cancer Hospital
    Changchun, 132013, China
  • Fujian Medical University Union Hospital
    Fuzhou City, 350001, China
  • Sun Yet-sen University Cancer Center
    Guangzhou City, 510663, China
  • Guangdong General Hospital
    Guangzhou, 510080, China
  • Harbin Medical University Cancer Hospital
    Harbin, 150081, China
  • Shandong Cancer Hospital
    Jinan, 250117, China
  • Jiangsu Province Hospital
    Nanjing, 210008, China
  • Fudan University Shanghai Cancer Center
    Shanghai City, 200120, China
  • Shanghai Jiao Tong University School of Medicine (SJTUSM) - Ruijin Hospital (GuangCi Hospital)
    Shanghai, 200025, China
  • Zhejiang Cancer Hospital
    Zhejiang, 310022, China
  • Henan Cancer Hospital
    Zhengzhou, 450008, China
  • Kyungpook National University Medical Center
    Daegu, 41404, Korea, Republic of
  • Ajou University Medical Center
    Gyeonggi-do, 16499, Korea, Republic of
  • Korea University Guro Hospital
    Seoul, 08308, Korea, Republic of
  • Taipei Medical University ?Shuang Ho Hospital
    New Taipei City, 23561, Taiwan
  • China Medical University Hospital; Surgery
    Taichung, 404, Taiwan
  • Mackay Memorial Hospital; Dept of Surgery
    Taipei, 104, Taiwan
  • Taipei Medical University Hospital
    Taipei, 110, Taiwan
  • Bhumibol Adulyadej Hospital; Medicine
    Bangkok, 10220, Thailand
  • Srinagarind Hospital, Khon Kaen University; Surgery
    Khon Kaen, 40002, Thailand
  • Songklanagarind Hospital; Department of Surgery
    Songkla, 90110, Thailand
09

References and documents

Publications

  • Shao Z, Pang D, Yang H, Li W, Wang S, Cui S, Liao N, Wang Y, Wang C, Chang YC, Wang H, Kang SY, Seo JH, Shen K, Laohawiriyakamol S, Jiang Z, Li J, Zhou J, Althaus B, Mao Y, Eng-Wong J. Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020 Mar 1;6(3):e193692. doi: 10.1001/jamaoncol.2019.3692. Epub 2020 Mar 12. PubMed 31647503 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Oct 2017, 19 months.

Results were first posted in Jan 2019, 1 year 2 months after primary completion.

Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 19 months is below that.

Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2015
First posted
Oct 26, 2015
StartActual
Mar 14, 2016
Primary completionActual
Oct 23, 2017
CompletionActual
Mar 14, 2022
Results first posted
Jan 3, 2019
Last update
May 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02586025
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 26, 2015
Start date
Mar 14, 2016
Primary completion
Oct 23, 2017
Completion
Mar 14, 2022
Results posted
Jan 3, 2019
Last update
May 22, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion